Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE: Risk of cancer in BRCA1 mutation carriers. Lancet. 1994, 343: 692-695. 10.1016/S0140-6736(94)91578-4.
Article
CAS
PubMed
Google Scholar
Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 mutations among Ashkenazi Jews. N Engl J Med. 1997, 336: 1401-1408. 10.1056/NEJM199705153362001.
Article
CAS
PubMed
Google Scholar
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber B, Prevention and Observation of Surgical End Points Study Group P: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002, 346: 1616-1622. 10.1056/NEJMoa012158.
Article
PubMed
Google Scholar
Rebbeck TR, Friebel T, Neuhausen SL, van't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE study group. J Clin Oncol. 2004, 22: 1055-1062. 10.1200/JCO.2004.04.188.
Article
PubMed
Google Scholar
Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, Parvin JD: BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA. 1997, 94: 5605-10. 10.1073/pnas.94.11.5605.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber BL, El-Deiry WS: BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene. 1998, 16: 1713-21. 10.1038/sj.onc.1201932.
Article
CAS
PubMed
Google Scholar
Welcsh PL, Owens KL, King M: Insight into the functions of BRCA1 and BRCA2. Trends Genet. 2000, 16: 69-74. 10.1016/S0168-9525(99)01930-7.
Article
CAS
PubMed
Google Scholar
Gowen LC: Brca1 deficiency results in early embryonic lethality characterised by neuroepitheilial. Nat Genet. 1996, 12: 191-1194. 10.1038/ng0296-191.
Article
CAS
PubMed
Google Scholar
Hakem R: The tumour suppressor gene Brca1 is required for early embryonic cellular proliferation in the mouse. Cell. 1996, 85: 1009-1023. 10.1016/S0092-8674(00)81302-1.
Article
CAS
PubMed
Google Scholar
Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA: p53 mutations in BRCA1-associated familial breast cancer. Lancet. 1997, 350: 638-639. 10.1016/S0140-6736(05)63327-2.
Article
CAS
PubMed
Google Scholar
Cressman VL, Backlund DC, Hicks EM, Gowen LC, Godfrey V, Koller BH: Mammary tumour formation in p53-and BRCA1 deficient mice. Cell Growth Differ. 1999, 10: 1-10.
CAS
PubMed
Google Scholar
Phillips KA: Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol. 1999, 18 (21s): 107s-112s.
Google Scholar
Lakhani SR, Van de Vijer MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: The pathology of familial breast cancer: Predictive value of immunohistochemical markers oestrogen receptor, PR, HER-2 and p53 in patients with mutations in BRCA1 and 2. J Clin Oncol. 2002, 20: 2310-2318. 10.1200/JCO.2002.09.023.
Article
CAS
PubMed
Google Scholar
Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benitez J: Phenotypic characterisation of BRCA1 and BRCA2 tumours based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat. 2005, 90: 5-14. 10.1007/s10549-004-1536-0.
Article
CAS
PubMed
Google Scholar
Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW: Partial rescue of Brca1 early embryonic lethality by p53 or p21 null mutation. Nature Genetics. 1997, 16: 298-302. 10.1038/ng0797-298.
Article
CAS
PubMed
Google Scholar
Ludwig T, Chapman DL, Papioannou VE, Efstratiadis A: Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of BRCA1, Brca2, Brca1/Brca2, Brca1/p53 nullizygous embryos. Genes Dev. 1997, 11: 1226-41.
Article
CAS
PubMed
Google Scholar
Mak TW, Hakem A, McPherson JP, Shehabeldin A, Zablocki E, Migon E, Duncan GS, Bouchard D, Wakeham A, Cheung A, Karaskova J, Sarosi I, Squire J, Marth J, Hakem R: Brcal required for T cell lineage development but not TCR loci rearrangement. Nature Immunol. 2000, 1: 77-82. 10.1038/76868.
Article
CAS
Google Scholar
McPherson JP, Lemmers B, Hirao A, Hakem A, Abraham J, Abraham J, Migon E, Matysiak-Zablocki E, Tamblyn L, Sanchez-Sweatman O, Khokha R, Squire J, Hande MP, Mak TW, Hakem R: Collaboration of Brca1 and Chk2 in tumourigenesis. Genes Dev. 2004, 18: 1144-53. 10.1101/gad.1192704.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bond GL, Hu W, Bond EE, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang S-J, Strong LC, Lozano G, Levine AJ: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumour suppressor pathway and accelerates tumour formation in humans. Cell. 2004, 119: 591-602. 10.1016/j.cell.2004.11.022.
Article
CAS
PubMed
Google Scholar
Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992, 358: 80-3. 10.1038/358080a0.
Article
CAS
PubMed
Google Scholar
Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP, Finlay CA: Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 1997, 11: 714-25.
Article
CAS
PubMed
Google Scholar
Alt JR, Bouska A, Fernandez MR, Cerny RL, Xiao H, Eischen CM: MDM2 binds to nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem. 2005, 280: 18771-81. 10.1074/jbc.M413387200.
Article
CAS
PubMed
Google Scholar
Buesmo-Ramos CE, Manshouri T, Haidar MA, Yang Y, McCown P, Ordonez N, Glassman A, Sneige N, Albitar M: Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat. 1996, 37: 179-88. 10.1007/BF01806499.
Article
Google Scholar
Freedman DA, Levine AJ: Regulation of the p53 protein by the MDM2 oncoprotein – thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1999, 59: 1-7.
CAS
PubMed
Google Scholar
Campbell IG, Eccles DM, Choong DYH: No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Letts. 2005,
Google Scholar
Foulkes WD, Stamp GW, Afzal S, Lalani N, McFarlane CP, Trosdale J, Campbell IG: MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer. 1995, 72: 883-8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ramus SJ, Bobrow LG, Pharoah PD, Finnigan DS, Fishman A, Altaras M, Harrington PA, Gayther SA, Ponder BAJ, Friedman LS: Increased frequency of TP 53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer. 1999, 25: 91-96. 10.1002/(SICI)1098-2264(199906)25:2<91::AID-GCC3>3.0.CO;2-5.
Article
CAS
PubMed
Google Scholar
Bond GL, Hu W, Levine A: A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005, 65: 5481-5484. 10.1158/0008-5472.CAN-05-0825.
Article
CAS
PubMed
Google Scholar
Alhopuro P, Ylisaukko-oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, Mecklin JP, Atula T, Kontio R, Makitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonem L-M, Aaltonen AA: The MDM2 promoter polymorphism SNP309T>G and the risk of uterine leiomyosarcoma, colorectal cancer and squamous cell carcinoma of the head and neck. J Med Genet. 2005, 42: 694-698. 10.1136/jmg.2005.031260.
Article
CAS
PubMed
PubMed Central
Google Scholar